Therapeutic prospect of Syk inhibitors

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 10, 2009, Pages 1361-1376

  Ruzza, Paolo ^a   Biondi, Barbara ^a   Calderan, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

ATP competitive inhibitors; Interfering RNA; Protein tyrosine kinase; Syk kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BAY 61 3606; CURCUMIN; GLUCOCORTICOID; IMATINIB; INDOLE DERIVATIVE; METHOTREXATE; NAPHTHYRIDINE DERIVATIVE; OXSI 2; PICEATANNOL; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PYRIMIDINE DERIVATIVE; R 112; R 343; R 406; R 788; SMALL INTERFERING RNA; STAUROSPORINE; UNCLASSIFIED DRUG; YM 193306;

ALLERGIC ASTHMA; ASTHMA; BINDING SITE; CLINICAL TRIAL; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE EXPRESSION; HAY FEVER; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; BINDING SITES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 70349781325     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903207039     Document Type: Review

References (110)

1. Levitzki A. Signal-transduction therapy. Eur J Biochem 1994;226:1-13
2. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-730
3. Vieth M, Sutherland JJ, Robertson DH, et al. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 2005;10:839-846 (Pubitemid 40824738)
4. Chan AC. Syk family of protein tyrosine kinases. Encycl Biol Chem 2004;4:139-145
5. Inazu T, Yamamura H. Signal transduction factor. Syk. Jikken Igaku 1994;12:370-371
6. Fukuda T, Suzuki Y, Yamanashi Y, et al. Role of the non-receptor type protein-tyrosine kinase substrates in signal transduction upon stimulation of B-cell antigen receptors. In: Yakura H, editor, Kinases Phosphatases Lymphocyte Neuronal Signaling. Tokyo: Springer 1997. p. 122-133
7. Kepley CL, Wilson BS, Oliver JM. Identification of the FcεRI-activated tyrosine kinases Lyn, Syk, and Zap-70 in human basophils. J Allergy Clin Immunol 1998;102:304-315
8. Taniguchi T, Kobayashi T, Kondo J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein- tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991;266:15790-15796 (Pubitemid 21907727)
9. Law C, Sidorenko S, Chandran K, et al. Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex. J Biol Chem 1994;269:12310-12319 (Pubitemid 24196738)
10. Sada K, Takano T, Yanagi S, et al. Structure and function of Syk protein-tyrosine kinase. J Biochem (Tokyo) 2001;130:177-186 (Pubitemid 32785863)
11. Arias-Palomo E, Recuero-Checa MA, Bustelo XR, et al. 3D structure of Syk kinase determined by single-particle electron microscopy. BBA Proteins Proteomics 2007;1774:1493-1499 (Pubitemid 350235353)
12. Arias-Palomo E, Recuero-Checa MA, Bustelo XR, et al. Conformational rearrangements upon Syk auto-phosphorylation. BBA Proteins Proteomics 2009;1794:1211-1217
13. Roskoski R. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004;324:1155-1164 (Pubitemid 40292143)
14. Deindl S, Kadlecek TA, Brdicka T, et al. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell 2007;129:735-746 (Pubitemid 46802380)
15. Tsang E, Giannetti AM, Shaw D, et al. Molecular mechanism of the Syk activation switch. J Biol Chem 2008;283:32650-32659
16. Latour S, Veillette A. Proximal protein tyrosine kinases it immunoreceptor signaling. Curr Opin Immunol 2001;13:299-306 (Pubitemid 32537701)
17. Futterer K, Wong J, Grucza RA, et al. Structural basis for syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 1998;281:523-537 (Pubitemid 28372129)
18. Folmer RHA, Geschwindner S, Xue YF. Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two bikes rather than a tandem. Biochemistry 2002;41:14176-14184 (Pubitemid 35403336)
19. Kurosaki T, Johnson SA, Pao L, et al. Role of the Syk autophosphorylation site and Sh2 domains in B-cell antigen receptor signaling. J Exp Med 1995;182:1815-1823
20. Ottinger EA, Botfield MC, Shoelson SE. Tandem SH2 domains confer high specificity in tyrosine kinase signaling. J Biol Chem 1998;273:729-735
21. Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol 2007;28:66-73
22. Wong WSF, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta Proteins Proteomics 2004;1697:53-69 (Pubitemid 38326761)
23. Wong BR, Grossbard EB, Payan DG, et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Invest Drugs 2004;13:743-762 (Pubitemid 39028928)
24. Ulanova M, Duta F, Puttagunta L, et al. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9:901-921 (Pubitemid 41488829)
25. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 2005;26:208-214 (Pubitemid 41556858)
26. Singh R, Masuda ES. Spleen tyrosine kinase (Syk) biology, inhibitors and therapeutic applications. Annu Rep Med Chem 2007;42:379-391
27. Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124:244-257 (Pubitemid 47247604)
28. Bahjat R, Reitsma A, Cassafer G, et al. An orally bioavailable kinase inhibitor delays disease progression in a murine model of systemic lupus erythematosus (SLE). Arthritis Rheum 2006;54:S453-4
29. Urich E, Gutcher I, Prinz M, et al. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci USA 2006;103:18697-18702 (Pubitemid 44913473)
30. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2008;23:686-697
31. Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006;108:4156-4162 (Pubitemid 44913287)
32. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006;176:5715-5719
33. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303-316 (Pubitemid 43381537)
34. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-2237
35. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 2007;178:111-121 (Pubitemid 46033592)
36. Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-855
37. Kuno Y, Abe A, Emi N, et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001;97:1050-1055 (Pubitemid 32154292)
38. Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006;20:313-318 (Pubitemid 43148670)
39. Wossning T, Herzog S, Kohler F, et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med 2006;203:2829-2840 (Pubitemid 46026161)
40. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500
41. Bailet O, Fenouille N, Abbe P, et al. Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res 2009;69:2748-2756
42. Bajpai M, Chopra P, Dastidar SG, et al. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs 2008;17(5):641-659 (Pubitemid 351843609)
43. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75:93-109 (Pubitemid 44118027)
44. Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco 2004;59:759-765 (Pubitemid 39335946)
45. Millenium Pharmaceuticals, Inc. Spleen tyrosine kinase catalytic domain: crystal structure and binding pockets thereof. WO2004035604; 2004
46. Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279:55827-55832 (Pubitemid 40066590)
47. Villaseñor AG, Kondru R, Ho H, et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des 2009;73:466-470
48. Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds their uses. WO2003063794; 2003
49. Rossi AB, Herlaar E, Braselmann S, et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol 2006;118:749-755 (Pubitemid 44301399)
50. Meltzer EO, Berkowitz RB, Grosshead EB, et al. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005;115:791-796
51. Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases. WO2005012294; 2005
52. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998-1008 (Pubitemid 44776446)
53. Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses. WO2006078846; 2006
54. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-3318
55. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-3160
56. Pfizer Limited Salt form. WO2009031011; 2009
57. Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c] pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306:1174-1181
58. Hisamichi H, Naito R, Toyoshima A, et al. Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorgan Med Chem 2005;13:4936-4951
59. Papp E, Tse JKY, Ho H, et al. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay. Biochemistry 2007;46:15103-15114 (Pubitemid 350308901)
60. Yamanouchi Pharmaceutical Co. Ltd. Novel pyrimidine-5-carboxamide derivatives. WO1999031073; 1999
61. Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives. WO2000075113; 2000
62. Hirabayashi A, Mukaiyama H, Kobayashi H, et al. A novel syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorg Med Chem 2008;16:7347-7357
63. Lai JYQ, Cox PJ, Patel R, et al. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett 2003;13:3111-3114 (Pubitemid 36993648)
64. Farmer LJ, Bemis G, Britt SD, et al. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 2008;18:6231-6235
65. Cywin CL, Zhao B-P, McNeil DW, et al. Discovery and SAR of novel [1,6] naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 2003;13:1415-1418
66. Boehringer Ingelheim Pharmaceutical, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase. WO2003057695; 2003
67. Aventis Pharma Ltd. Azaindoles. WO200147922; 2001
68. Oliver JM, Burg DL, Wilson BS, et al. Inhibition of mast cell FcεR1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 1984;269:29697-29703
69. Miura K, Lavens-Phillips S, MacGlashan DWJ. Piceatannol is an effective inhibitor of IgE-mediated secretion from human basophils but is neither selective for this receptor nor acts on syk kinase at concentrations where mediator release inhibition occurs. Clin Exp Allergy 2001;31:1732-1739 (Pubitemid 34204430)
70. Stenton GR, Kim MK, Nohara O, et al. Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol 2000;164:3790-3797 (Pubitemid 30169836)
71. Stenton GR, Dery RE, Merani S, et al. Aerosolized Syk antisense suppresses antigen-dependent tracheal contraction, pulmonary inflammation and airway hyperresponsiveness. J Allergy Clin Immunol 2001;107:347
72. Stenton GR, Ulanova M, Dery RE, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169:1028-1036 (Pubitemid 34753463)
73. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta Gene Struct Expr 1999;1489:31-44
74. Crooke ST. Antisense strategies. Curr Mol Med 2004;4:465-487
75. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55:61-95
76. Matsuda M, Park JG, Wang DC, et al. Abrogation of the Fc gamma receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol Biol Cell 1996;7:1095-1106 (Pubitemid 26244206)
77. Bilanges B, Stokoe D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 2005;388:573-583 (Pubitemid 40839935)
78. Bock LC, Griffin LC, Latham JA, et al. Selection of single-stranded-DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-566
79. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of C-Myb and C-Myc antisense oligonucleotides in smooth-muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-4055
80. Cho YS, Kim MK, Cheadle C, et al. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc Natl Acad Sci USA 2001;98:9819-9823 (Pubitemid 32769387)
81. Fennewald SM, Rando RF. Inhibition of high-affinity basic fibroblast growth-factor binding by oligonucleotides. J Biol Chem 1995;270:21718-21721
82. Fisher AA, Ye DJ, Sergueev DS, et al. Evaluating the specificity of antisense oligonucleotide conjugates - A DNA array analysis. J Biol Chem 2002;277:22980-22984
83. Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth-factor, inhibit its binding to cell-surface receptors, and remove it from low-affinity binding-sites oil extracellular-matrix. J Biol Chem 1995;270:2620-2627
84. Hannon GJ. RNA interference. Nature 2002;418:244-251
85. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-747
86. Williams BRG. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans 1997;25:509-513 (Pubitemid 27260861)
87. Schwarz DS, Hutvagner G, Haley B, et al. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 2002;10:537-548 (Pubitemid 35284172)
88. Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101:25-33
89. Clarke PA, Mathews MB. Interactions between the double-stranded-Rna binding motif and Rna-definition of the binding-site for the interferon-induced protein-kinase dai (Pkr) on adenovirus va Rna. RNA Publ RNA Soc 1995;1:7-20
90. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-839 (Pubitemid 37087172)
91. Reynolds A, Anderson EM, Vermeulen A, et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA Publ RNA Soc 2006;12:988-993 (Pubitemid 43788117)
92. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-462 (Pubitemid 41724921)
93. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498 (Pubitemid 32494397)
94. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001;15:188-200 (Pubitemid 32107664)
95. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-958 (Pubitemid 34408544)
96. Wianny F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol 2000;2:70-75 (Pubitemid 30785916)
97. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23:222-226
98. Alcon Manufacturing, Ltd. RNAi-mediated inhbition of spleen tyrosine kinase-related inflammatory conditions. WO2007121347; 2007
99. Yale University. Syk-targeted nucleic acid interference. WO2005049838; 2005
100. The Trustees of the University of Pennsylvania. Inhibition of Syk kinase expression. WO2005007623; 2005
101. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178 (Pubitemid 39545841)
102. Heidenreich O, Gryaznov S, Nerenberg M. RNase H-independent antisense activity of oligonucleotide N3′->P5′ phosphoramidates. Nucleic Acids Res 1997;25:776-780 (Pubitemid 27299832)
103. Wilson WD, Mizan S, Taniuos FA, et al. The interaction of intercalators and groove-binding agents with DNA triple-helical structures: the influence of ligand structure, DNA backbone modifications and sequence. J Mol Recognit 1994;7:89-98 (Pubitemid 2126195)
104. Hirschbein BL, Fearon KL. P-31 NMR spectroscopy in oligonucleotide research and development - commentary. Antisense Nucleic Acid Drug Dev 1997;7:55-61
105. Handin RI, Stossel TP. Phagocytosis of antibody-coated platelets by human granulocytes. N Engl J Med 1974;290:989-993
106. Lim JY, Kim YG, Han K, et al. Flow cytometric monocyte phagocytic assay for predicting platelet transfusion outcome. Transfusion 2002;42:309-316
107. Wiener E, Abeyakoon O, Benchetrit G, et al. Anti-HPA-1a-mediated platelet phagocytosis by monocytes in vitro and its inhibition by Fc gamma receptor (Fc gamma R) reactive reagents. Eur J Haematol 2003;70:67-74 (Pubitemid 36269551)
108. Saitoh S, Arudchandran R, Manetz TS, et al. LAT is essential for Fc epsilon RI-mediated mast cell activation. Immunity 2000;12:525-535 (Pubitemid 30949334)
109. Nathan C. Points of control in inflammation. Nature 2002;420:846-852
110. Buckbinder L. The glucocorticoid receptor: molecular mechanisms and new therapeutic opportunities. Inflamm Res 2002;51:167-169 (Pubitemid 34457528)